TB-500 (Thymosin β4 fragment)

Fragment or Full Protein: Which the Research Uses

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

The heptapeptide isolates one functional motif, which makes it the cleaner choice when actin binding is the variable under study. Full-length thymosin beta-4 carries the whole molecule, which makes it the appropriate choice when the question concerns the protein's behaviour rather than the motif's.

Key facts

Use the fragment when
Actin binding is the variable
Use the protein when
The question is about Tβ4 itself
Fragment advantage
Attributability: one motif, one variable
Protein advantage
Biological completeness
Cost difference
Substantial (7 vs 43 residues)
Literature split
Actin work fragment; repair work protein

The experimental logic

Isolating a motif is a deliberate reduction. If the heptapeptide produces an effect, that effect is attributable to the motif, because nothing else is present. That is a real methodological strength, the same logic behind using a purified domain rather than a whole protein in mechanistic work.

What the reduction costs

Everything the rest of the protein does. Thymosin beta-4 is reported to have activities beyond actin sequestration, and a 43-residue protein presents surfaces and conformations a heptapeptide cannot. If a phenomenon depends on those, the fragment will not reproduce it, and a negative result with the fragment is then a statement about the motif rather than about the protein.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

Why the fragment might behave differently even on actin

Context matters even for a motif's own function. Within the protein, LKKTETQ sits in a defined structural setting; alone it is a short flexible peptide with free ends. Binding affinity and kinetics can differ between a motif in situ and the same sequence isolated, which is a standard finding in peptide work rather than a peculiarity of this system.

Reading the literature with this in mind

The practical consequence is that TB-500's literature is partly borrowed. Actin-sequestration findings sit closest to the fragment. Corneal wound healing, cardiac repair and much of the regenerative work used the protein. A claim about TB-500 supported by a citation using thymosin beta-4 has crossed a gap, and whether that gap matters depends on whether the effect runs through the motif.

The commercial reality

Cost dominates. Seven residues is routine; forty-three is a difficult synthesis with more deletion sequences and a much higher price. That is why the fragment is what the market calls TB-500, and why the mismatch between what is sold and what was studied persists rather than resolving.

Frequently asked questions

Is the fragment inferior to the protein?

Neither is inferior; they answer different questions. The fragment isolates a variable; the protein preserves biological completeness.

Would the fragment reproduce the protein's wound-healing results?

Not established. Those studies used the protein, and whether the effect runs through the LKKTETQ motif alone is an open question.

Does a motif behave the same alone as in a protein?

Not necessarily. Affinity and kinetics can differ between a motif in its structural context and the same sequence isolated.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More TB-500 (Thymosin β4 fragment) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.